Liraglutide and Βeta‐Cell Function in Young Adults With Long‐Standing Type 1 Diabetes and Residual C‐Peptide: A Blinded, Randomized Controlled Trial
Authors' conclusion
In adults with long-standing T1D, liraglutide did not preserve stimulated C-peptide after 52 weeks. Exploratory post hoc longitudinal analyses suggested a steeper decline in stimulated C-peptide with liraglutide than with placebo.
Study context
- Population
- Adults with T1D duration ≥ 5 years and detectable fasting C-peptide
- Participants
- 18 adults
- Comparison
- Liraglutide vs placebo for 52 weeks
- Primary endpoint
- Change in stimulated C-peptide AUC from baseline
- Follow-up
- Week 52
Methodological detailsblinded, placebo-controlled, Mixed-meal tolerance tests at baseline and weeks 6, 52 and 65
- Blinded
- Placebo-controlled
- Mixed-meal tolerance tests at baseline and weeks 6, 52 and 65
Primary result
As reported in the abstract
Stimulated C-peptide
- Liraglutide did not improve stimulated C-peptide vs placebo
Further findings
Stimulated C-peptide and insulin requirements, post-treatment period · weeks 0-65
- Stimulated C-peptide declined more steeply with liraglutide than placebo, with increasing insulin requirements over time
- Exploratory post hoc longitudinal analyses
Original publication
Liraglutide and Βeta‐Cell Function in Young Adults With Long‐Standing Type 1 Diabetes and Residual C‐Peptide: A Blinded, Randomized Controlled Trial. Diabetes Obes Metab. Published 13 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →